
Opinion|Videos|August 15, 2024
Experts Review Pirtobrutinib Clinical Data and Share its Utilization in Practice
A medical expert offers commentary on the recent FDA accelerated approval of pirtobrutinib, discussing the implications of the BRUIN trial findings that supported this decision for chronic lymphocytic leukemia treatment.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Briefly comment on the recent FDA accelerated approval granted to pirtobrutinib based on findings from BRUIN.
- How are you currently using pirtobrutinib in the clinical practice setting and how do you sequence it with other available therapies?
- Is there a potential role for pirtobrutinib in earlier lines of therapy?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5




































